Biden administration to retire 'Operation Warp Speed' name
January 15, 2021 -- The incoming Biden administration said that it will no longer use the "Operation Warp Speed" term to describe the U.S. government's efforts to combat the COVID-19 pandemic.
Precision Medicine acquires Project Farma
January 15, 2021 -- Precision Medicine has acquired Project Farma, a bioengineering services firm.
Cognate BioServices expands manufacturing in U.S., Europe
January 15, 2021 -- Contract development and manufacturing organization Cognate BioServices plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and to increase office support at its facilities in the U.S. and Europe.
RoosterBio, Sartorius partner on cell and gene therapy manufacturing
January 15, 2021 -- RoosterBio and Sartorius have signed a strategic collaboration to advance the scale-up of human mesenchymal stem/stromal cells manufacturing for regenerative medicines.
Nucleai and Debiopharm team up in AI-based cancer drug development
January 14, 2021 -- Biomarker discovery company Nucleai will be working with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per a new research collaboration.
Startup Creative Bio launches cell culture portfolio
January 14, 2021 -- Creative Bio has launched a portfolio of cell culture tools that it hopes will be useful during the COVID-19 pandemic.
Thermo Fisher subsidizes more sequencers for global coronavirus research
January 14, 2021 -- Thermo Fisher Scientific is expanding a global SARS-CoV-2 program that provides its next-generation sequencers at subsidized prices to help analyze new strains of the virus and for tracing community transmission.
Bone Therapeutics, Rigenerand partner on cell therapy process development
January 14, 2021 -- Bone Therapeutics and Rigenerand have formed a cell therapy process development partnership.
Tonix files patent for proprietary monoclonal antibody
January 14, 2021 -- Tonix Pharmaceuticals has filed a patent application for TNX-1500, a humanized monoclonal antibody (mAb) directed against the CD40-ligand, with the World Intellectual Property Organization.
Lentigen to manufacture vector for Oncternal
January 14, 2021 -- Oncternal Therapeutics announced an agreement with Lentigen Technology, a subsidiary of Miltenyi Biotec, to manufacture lentiviral vectors for Octernal's investigational receptor tyrosine kinase-like orphan receptor 1-targeting chimeric antigen receptor T-cell therapy program.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter